Product Details for NDA 022173
ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
EQ 210MG BASE/VIAL
Marketing Status: Prescription
EQ 300MG BASE/VIAL
Marketing Status: Prescription
EQ 405MG BASE/VIAL
Marketing Status: Prescription
EQ 210MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 210MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022173
Product Number: 001
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 210MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022173
Product Number: 001
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
EQ 300MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 300MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022173
Product Number: 002
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
ZYPREXA RELPREVV (OLANZAPINE PAMOATE)
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 300MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N022173
Product Number: 002
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
EQ 405MG BASE/VIAL
Marketing Status: Prescription
Active Ingredient: OLANZAPINE PAMOATE
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 405MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N022173
Product Number: 003
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: ZYPREXA RELPREVV
Dosage Form; Route of Administration: SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
Strength: EQ 405MG BASE/VIAL
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N022173
Product Number: 003
Approval Date: Dec 11, 2009
Applicant Holder Full Name: CHEPLAPHARM REGISTRATION GMBH
Marketing Status: Prescription
Patent and Exclusivity Information